Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(9):624-626; doi:10.1093/jnci/97.9.624
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vanchieri, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vanchieri, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

When Will the U.S. Flinch at Cancer Drug Prices?

Cori Vanchieri

The first 150 words of the full text of this article appear below.

High hopes in cancer research are pinned on the targeted therapies—those that aim directly at cancer cells or that cut off a tumor's blood supply without harming healthy tissue. And 2004 was a banner year for such drugs reaching the marketplace; Avastin (bevacizumab), Erbitux (cetuximab), Tarceva (erlotinib), and Iressa (gefitinib) all became available to great fanfare.

With their approval came sticker shock because some of the drugs were priced at thousands of dollars per month of treatment and were only effective as add-ons to other therapies. Clinicians are wondering whether these new cancer treatments—which may, on average, add only a few months of survival—are worth the cost.

"America doesn't want to ask the question," said Bruce E. Hillner, M.D., of Virginia Commonwealth University in Richmond. "We're not willing to accept limits, so we'll put off that discussion." Hillner has been doing cost-effectiveness analyses for 15 years. He said the response . . . [Full Text of this Article]

Colon Cancer Leads the Way

Access to Care

Societal Costs

Rising Costs of Chemotherapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
B. E. Hillner and T. J. Smith
Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?
J. Clin. Oncol., February 20, 2007; 25(6): 611 - 613.
[Full Text] [PDF]

Home page
 The OncologistHome page
E. A. Perez
Appraising Adjuvant Aromatase Inhibitor Therapy
Oncologist, November 1, 2006; 11(10): 1058 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
U. Emmenegger, G. C. Morton, G. Francia, Y. Shaked, M. Franco, A. Weinerman, S. Man, and R. S. Kerbel
Low-Dose Metronomic Daily Cyclophosphamide and Weekly Tirapazamine: A Well-Tolerated Combination Regimen with Enhanced Efficacy That Exploits Tumor Hypoxia
Cancer Res., February 1, 2006; 66(3): 1664 - 1674.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Emmenegger and R. S. Kerbel
A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs
Clin. Cancer Res., November 1, 2005; 11(21): 7589 - 7592.
[Full Text] [PDF]